MDMA, commonly referred to as “ecstasy” or “molly," is on its way to becoming the first psychedelic to receive approval from the Food and Drug Administration (FDA) after a new study conducted by an industry-leading research group found that the drug was effective in treating moderate and severe post-traumatic stress disorder (PTSD) among a racially diverse set of patients. After successfully carrying out an 18-week Phase 3 clinical trial, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced this week that almost 90 percent of participants who were treated with MDMA-AT — methylenedioxymethamphetamine-assisted therapy — “achieved a clinically meaningful benefit” w
Hence then, the article about new study brings mdma as treatment for ptsd closer to fda approval was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( New study brings MDMA as treatment for PTSD closer to FDA approval )